Fig. 5

MiR-329-3p directly targeted NEK2. a The binding sites between miR-329-3p and NEK2, as well as the mutant. b, c Dual-luciferase reporter assay for the luciferase activity in glioma U251 and LN229 cells cotransfected with NEK2 3′UTR-WT or NEK2 3′UTR-MUT and miR-329-3p or miR-NC. d QRT-PCR assay for the relative mRNA expression of NEK2 in glioma tissues and normal tissues. e Pearson correlation analysis for the correlation between the expression of miR-329-3p and NEK2 in glioma tissues. R = − 0.515, P < 0.0001. f Western blot assay for the protein level of NEK2 in glioma tissues and normal tissues. g QRT-PCR assay for the relative mRNA expression of NEK2 in glioma U251 and LN229 cells and NHA. h Western blot assay for the protein level of NEK2 in glioma U251 and LN229 cells and NHA. i QRT-PCR assay for the relative mRNA expression of NEK2 in U251 and LN229 cells transfected with miR-NC, miR-329-3p, miR-329-3p + pcDNA-NC or miR-329-3p + pcDNA-NEK2. j Western blot assay for the protein level of NEK2 in U251 and LN229 cells transfected with miR-NC, miR-329-3p, miR-329-3p + pcDNA-NC or miR-329-3p + pcDNA-NEK2. *P < 0.05